BioNTech SE

BioNTech SE engages in the development of novel medicines at the intersection of immunology and synthetic biology. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioNTech reports robust 2022 earnings, eyes growth in oncology and infectious diseases

BioNTech's strong financial performance in 2022 sets the stage for continued growth in 2023, with a focus on expanding its vaccine portfolio, advancing oncology programs, and navigating the evolving landscape of COVID-19. The company's strategic priorities align with market demands for infectious disease and oncology solutions, positioning BioNTech for future success and profitability.

BioNTech posts robust Q1 results, eyes growth in vaccines and oncology

BioNTech's Q1 2023 performance reflects strong financial results and promising developments in its vaccine and oncology programs.
While facing challenges such as seasonal trends and data constraints, the company is strategically positioned to leverage opportunities in commercial planning and therapeutic advancements.
With a focus on synergistic partnerships and innovative technologies, BioNTech aims to maintain its competitive edge in the biopharmaceutical industry.
The company's commitment to enhancing existing platforms and exploring new growth avenues underscores its resilience and adaptability in a dynamic market environment.

BioNTech reports mixed Q2 results, focuses on innovation and growth

BioNTech's Q2 2023 performance reflects a mix of strong revenue generation and financial challenges, emphasizing the importance of strategic focus.
The company's strengths lie in its innovative collaborations, pipeline advancements, and preparedness for market demands, despite facing financial losses.
Navigating challenges in financial sustainability, market competition, and stakeholder communication will be crucial for BioNTech's future growth and success.

BioNTech adjusts revenue guidance amidst vaccine demand challenges

BioNTech's Q3 2023 performance reflected revenue challenges from lower COVID-19 vaccine demand and write-downs, prompting revised revenue guidance.
Despite challenges, the company showcased strengths in vaccine development, oncology advancements, and strategic cost management initiatives.
Opportunities lie in shared R&D expenses, long-term growth prospects from combination vaccines, and maintaining financial strength during market transition.

BioNTech reports strong Q4 earnings, eyes diversified product expansion

BioNTech is strategically investing in expanding its product portfolio while navigating uncertainties in COVID-19 vaccine revenues. The company aims to transform into a multiproduct company by 2030, focusing on oncology and infectious diseases.

BioNTech advances oncology pipeline, eyes growth amid financial challenges

BioNTech is making significant strides in its oncology pipeline, aiming for multiple product launches by 2026 and focusing on cancer vaccines and mRNA treatments.
While facing financial losses and short-term profitability challenges, the company remains optimistic about its growth trajectory and revenue potential.
Strategic investments in technology platforms, commercial readiness, and partnerships position BioNTech for sustainable growth and value enhancement.
Balancing cost control, revenue generation, and clinical execution will be crucial for BioNTech to capitalize on opportunities and navigate challenges effectively.

BioNTech reports Q2 progress in oncology pipeline amid financial challenges

BioNTech's Q2 2024 earnings call highlighted progress in oncology and COVID-19 vaccines, with total revenues of EUR 129 million but a net loss of EUR 808 million. The company remains focused on advancing innovative therapies and expanding its global manufacturing capabilities.

BioNTech reports robust Q3 earnings, focuses on oncology pipeline

BioNTech's Q3 2024 performance was strong, driven by COVID-19 vaccines and oncology trials.
While facing revenue challenges in certain regions, the company remains focused on growth.
Opportunities lie in advancing oncology pipeline and demonstrating product potential.
Maintaining a strong cash position provides flexibility for future investments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Moderna

Pfizer

Hubbell

Lululemon Athletica

Manchester United

Novavax

Shares of Lululemon Athletica Inc. LULU, +1.00% rallied more than 5% after index provider S&P Dow Jones Indices said the stock will join the S&P 500 index SPX on Wednesday.

Pfizer shares fall on guidance cut, weighing on BioNTech and Moderna stocks, and other shares on the move

Germany's BioNTech on Monday said it would likely take write-downs of up to 900 million euros ($947 million) in the third quarter after its partner Pfizer reported similar charges on their COVID-19 vaccine business last week.

BioNTech will likely take 900 mln eur write-off on Pfizer-partnered vaccines

MAINZ, Germany, October 16, 2023 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present data across its oncology pipeline, covering multiple solid tumor types and novel mechanisms of action, at the European Society for Molecular Oncology (“ESMO”) Congress 2023 in Madrid, Spain from October 20-24, 2023. The updates will feature oral and poster presentations for five candidates of BioNTech's clinical pipeline across the Company's drug classes, which comprise mRNA-based immunotherapies, cell therapies, protein-based therapeutics, and small molecules.

BioNTech to Present Multiple Program Updates Across Modalities at ESMO Congress 2023

MAINZ, Germany, October 16, 2023 (GLOBE NEWSWIRE) -- On October 13, 2023, Pfizer Inc. (NYSE: PFE, “Pfizer”), a collaboration partner of BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”), announced a non-cash charge for inventory write-offs and other charges related to COMIRNATY of $0.9 billion. The Company has been informed by Pfizer that the majority of the write-offs relate to raw materials, mainly formulation-related lipids, purchased during the pandemic, as well as COVID-19 vaccine doses adapted to other, non-XBB.1.5 variants produced at risk. According to Pfizer, the write-offs do not address Pfizer-BioNTech COVID-19 Vaccine doses adapted to the XBB.1.5 variant, which has been approved and is being marketed in key geographies.

Update Regarding Pfizer's Statement on COMIRNATY-Related Write-Offs

Vaccine stocks delivered multibagger returns earlier in the pandemic. Their performance has suffered in recent times as some investors worry about revenue in a post-pandemic world.

The COVID Vaccine Market Is Changing Dramatically. Do Vaccine Stocks Still Make Good Investments?

Adobe

Analog Devices

Bristol-Myers

Ford Motor Company

MongoDB

NVIDIA

Artificial intelligence. New pharmaceutical drugs.

7 Innovator Stocks Primed for Exceptional Growth

Harnessing mRNA technology, BioNTech is poised to lead the oncology market with innovative treatments. BNTX expects a sustainable revenue stream by addressing evolving COVID-19 variants. With a substantial cash reserve, the Company strategically invests in acquisitions and partnerships.

BioNTech: This Beaten Pandemic Star Will Capitalize On Oncology Treatments

Brookfield Infrastructure Partners L.P.

PayPal

BioNTech's pipeline is loaded with promising candidates. PayPal Holdings is dirt cheap and is delivering solid earnings growth.

3 Stocks to Buy in October That Could Soar More Than 40% Over the Next 12 Months, According to Wall Street

While people in this country aren't rushing in masses to get updated COVID booster vaccines, take-up has been encouraging. Many are worried about an apparent resurgence in the affliction.

Why Pfizer and BioNTech Stocks Zoomed Higher Today

KIRKLAND, QUEBEC and MAINZ, GERMANY, September 28, 2023 — Pfizer Canada ULC and BioNTech SE (Nasdaq: BNTX, “BioNTech”) announced today that Health Canada has authorized the companies' Omicron XBB.1.5-adapted monovalent COVID-19 vaccine (COMIRNATY® Omicron XBB.1.5) for ages 6 months and older. The updated vaccine will be available in Canada as a single dose for individuals 5 years of age and older, regardless of prior COVID-19 vaccination history. For children 6 months through 4 years of age the updated vaccine is authorized for administration as a three-dose series in those without a history of completion of a COVID-19 primary vaccination course, or as a single dose for those with a history of completion of a COVID-19 primary vaccination course.

Pfizer and BioNTech Receive Health Canada Authorization for XBB.1.5-Adapted Monovalent COVID-19 Vaccine

In the ever-evolving world of the stock market, uncovering potential gold mines is paramount for smart investing. One promising area to consider is undervalued biotech stocks.

Undervalued Biotech Stocks Shine: Pfizer and BioNTech Show Resilience

A German court on Thursday suspended a patent trial against BioNTech over the use of mRNA technology in the COVID-19 vaccine developed by the German company together with its U.S. partner Pfizer.

German court suspends mRNA patent trial against BioNTech

Facing significant patent cliffs, Pfizer is putting faith in new launches. Moderna has nearly doubled its pipeline in three years.

With New COVID-19 Boosters in Tow, Which Is the Better Buy: Pfizer, BioNtech, or Moderna Stock?

Germany's BioNtech said on Monday it is entering into a partnership with the Coalition for Epidemic Preparedness Innovations (CEPI) to advance the development of its mpox vaccine.

BioNTech partners with CEPI to advance development of mpox vaccine

BioNTech SE BNTX, -0.66% and the Norwegian-based Coalition for Epidemic Preparedness Innovations, or CEPI, said Monday they are partnering to advance an mRNA-based Mpox vaccine. BioNTech will start a Phase 1/2 clinical trial of the vaccine called BNT166, while CEPI will commit funding if up to $90 million for the program.

BioNTech and CEPI to partner to advance an mRNA-based Mpox vaccine

MAINZ, Germany, and OSLO, Norway, September 18, 2023 — BioNTech SE (Nasdaq: BNTX, “BioNTech”, "the Company") and the  Coalition for Epidemic Preparedness Innovations  (CEPI) today announced a strategic partnership to advance mRNA-based vaccine candidates with the development of BNT166 for the prevention of mpox (formerly monkeypox, caused by a member of the Orthopoxvirus viral family), an infectious disease that can lead to severe, life-threatening complications. Mpox gained global attention in May 2022 with an increasing number of cases that then developed into an international outbreak.1,2 CEPI will provide funding of up to $90 million to support the development of mRNA-based vaccine candidates.

BioNTech and CEPI Announce Partnership to Advance mRNA Mpox Vaccine Development and Support CEPI's 100 Days Mission

Recent surges in COVID cases and public interest could drive revenue once again in the near future. However, this renewed attention is also likely to boost investment interest in companies. BioNTech has made significant strides in advancing its pipeline, including advancement with BNT316/ONC-392, a potential treatment for Non-Small Cell Lung cancer that posts a significant market opportunity. Cancer continues to affect a growing population. The BioNTech pipeline holds a variety of candidates addressing these different types, aiming to capture future market share in the multibillion-dollar field of oncology.

BioNTech: Renewed COVID Focus Might Spark Potential Share Price Boost

Pfizer (PFE)/ BioNTech (BNTX), and Moderna's (MRNA) updated mRNA vaccines are now approved for individuals 12 years of age and older and are authorized under emergency use for individuals 6 months through 11 years of age.

FDA Approves Pfizer & Moderna's New COVID Booster Vaccines

The updated booster shots arrive as new coronavirus variants circulate.

FDA Approves New Covid Vaccines To Target Latest Strains

The U.S. health regulator on Monday authorized updated COVID-19 vaccines that closely match the Omicron variants that are circulating, starting the process to deploy the shots this month.

US FDA authorizes updated COVID vaccines

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. Food and Drug Administration (FDA) approved the supplemental Biologics License Application (COMIRNATY 2023-2024 Formulation) for individuals 12 years and older and granted emergency use authorization for individuals 6 months through 11 years of age for the companies' Omicron XBB.1.5-adapted monovalent COVID-19 vaccine. This season's vaccine is indicated as a single do.

Pfizer and BioNTech Receive U.S. FDA Approval for 2023-2024 COVID-19 Vaccine

An updated Covid-19 vaccine made by Pfizer Inc (NYSE:PFE) and BioNTech has been approved by the UK medical regulator, amid a rise in new variants and subvariants of the virus. The new Pfizer-BioNTech vaccine targets the Omicron XBB.1.5 subvariant, which was approved in the European Union last week, was given approved by the UK Medicines & Healthcare products Regulatory Agency (MHRA) on Tuesday, to be given to anyone aged six months or above.

UK joins EU in approving XBB.1.5 jab from Pfizer-BioNTech, but others subvariants are emerging

The UK drug regulator said on Tuesday it has approved an updated COVID-19 vaccine by Pfizer and its German partner BioNTech that targets only the Omicron XBB.1.5 subvariant.

UK regulator approves updated Pfizer-BioNTech COVID vaccine

BioNTech's Q2 2023 revenues significantly decreased due to declining COVID-19 vaccine sales, but the company holds $15.3B in cash reserves. The company's pipeline includes COVID-19 vaccine developments and promising oncology initiatives. The emergence of new COVID-19 variants highlights the potential for ongoing vaccine demand, but public trust and acceptance are crucial.

BioNTech: Not Just Another Jab In The Arm

Pfizer Inc. PFE, -0.25% and BioNTech SE BNTX, +0.58% said Wednesday that its updated COVID-19 vaccine, which is tailored to the new Omicron XBB.1.5 variant has been recommended to receive marketing approval by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). The recommendation is for the updated vaccine to be administered as a single dose to those who are at least five years old, regardless of COVID vaccination history.

News for BioNTech SE Stock (BNTX)